<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539964</url>
  </required_header>
  <id_info>
    <org_study_id>SPM-020</org_study_id>
    <nct_id>NCT04539964</nct_id>
  </id_info>
  <brief_title>Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis</brief_title>
  <acronym>RESET-RA</acronym>
  <official_title>Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SetPoint Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SetPoint Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device)&#xD;
      for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who&#xD;
      have had an inadequate response or intolerance to biologic or targeted synthetic&#xD;
      Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized&#xD;
      stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve&#xD;
      through a small incision on the left side of the neck (implant procedure). The study will&#xD;
      enroll 250 subjects at 40 sites. All eligible subjects will undergo the implant procedure.&#xD;
      Half of the subjects will receive active stimulation (treatment) and the other half will&#xD;
      receive non-active stimulation (control). After completing primary endpoint assessments at&#xD;
      Week 12, there will be a one-way crossover of control subjects to active stimulation and a&#xD;
      180-week open-label follow-up with all subjects (treatment and control) receiving active&#xD;
      stimulation to evaluate long-term safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RESET-RA study is an operationally seamless, 2-stage, randomized, double-blind,&#xD;
      sham-controlled, multicenter pivotal study enrolling 250 subjects at 40 study centers across&#xD;
      the U.S. The study will assess the safety and efficacy of the SetPoint System (study device)&#xD;
      for the treatment of adult patients with active, moderate to severe rheumatoid arthritis (RA)&#xD;
      who have had an inadequate response, loss of response or intolerance to biologic or targeted&#xD;
      synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a&#xD;
      miniaturized stimulator (implant) that is surgically implanted inside the left side of the&#xD;
      neck on the vagus nerve (implant procedure). The implant delivers a small amount of&#xD;
      electricity (stimulation) to the nerve. All eligible subjects will undergo the surgery under&#xD;
      general anesthesia. Half of the subjects will receive active stimulation (the treatment&#xD;
      group) and the other half will receive non-active stimulation (the control group).&#xD;
      Stimulation will be delivered for 1 min once per day for 12 weeks. After completing primary&#xD;
      endpoint assessments at Week 12, there will be a one-way crossover of control subjects to&#xD;
      active stimulation and a 180-week open-label follow-up with all subjects (treatment and&#xD;
      control) receiving active stimulation to evaluate long-term safety. Blinding will be&#xD;
      maintained until the last enrolled and randomized subject in Stage 2 completes Week 12&#xD;
      assessments, and the study database is locked.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">May 2027</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An operationally seamless, 2-stage, randomized, double-blind, sham-controlled, multicenter study. Subjects will be assigned randomly in a 1:1 ratio into either a treatment or control group. Subjects assigned to the treatment group will receive active stimulation for 1 min once per day, and those assigned to the control group will receive non-active stimulation for 1 min once per day.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All subjects, investigators, joint evaluators and study staff will be blinded. Blinding of subjects, joint evaluators and investigators will be assessed at Weeks 4 and 12.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the American College of Rheumatology (ACR) 20 response</measure>
    <time_frame>Week 12</time_frame>
    <description>Difference between treatment and control groups in the proportion of subjects who achieve at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worse) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worse), subject pain (0=no pain to 10=worse), evaluator's global assessment (0=best to 10=worse), or high sensitivity C-reactive protein (hsCRP) concentration (mg/mL) with higher values representing worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Disease Activity Score 28-C-reactive protein (DAS28-CRP) good or moderate response as defined by European League Against Rheumatism (EULAR)</measure>
    <time_frame>Week 12</time_frame>
    <description>The DAS28-CRP good or moderate response as defined by EULAR based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worse), subject global assessment (0=best to 10=worse) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L) with higher values representing worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28-CRP response (MCID -1.2) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>DAS28-CRP response based on the minimal clinically important difference (MCID) of -1.2 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire Disability Index (HAQ-DI) response (MCID -0.22)</measure>
    <time_frame>Week 12</time_frame>
    <description>HAQ-DI response based on the MCID of -0.22 from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR20 response at Week 12 from Day 0</measure>
    <time_frame>Week 12</time_frame>
    <description>Difference between treatment and control groups in the proportion of subjects who achieve at least 20% improvement from Day 0 to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worse) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worse), subject pain (0=no pain to 10=worse), evaluator's global assessment (0=best to 10=worse), or high sensitivity C-reactive protein (hsCRP) concentration (mg/mL) with higher values representing worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active stimulation for 1 min once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Non-active stimulation for 1 min once per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Implant Procedure</intervention_name>
    <description>The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Surgical placement of vagus nerve stimulator inside the neck</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional Synthetic DMARD</intervention_name>
    <description>All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Background therapy with conventional synthetic DMARD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active stimulation</intervention_name>
    <description>Active stimulation for 1 min once per day</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-active stimulation</intervention_name>
    <description>Non-active stimulation for 1 min once per day</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  22-75 years of age at screening&#xD;
&#xD;
          -  Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints&#xD;
&#xD;
          -  Demonstrated an inadequate response, loss of response, or intolerance to 1 or more&#xD;
             approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying&#xD;
             Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi)&#xD;
&#xD;
          -  Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks&#xD;
             and on a continuous non-changing dose and route of administration for at least 4 weeks&#xD;
             prior to Screening and able to continue the same stable dose through Week 12&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated or poorly controlled psychiatric illness or history of substance abuse&#xD;
&#xD;
          -  Significant immunodeficiency due to underlying illness&#xD;
&#xD;
          -  History of stroke or transient ischemic attack, or diagnosis of cerebrovascular&#xD;
             fibromuscular dysplasia&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or&#xD;
             Parkinson's disease&#xD;
&#xD;
          -  Uncontrolled fibromyalgia&#xD;
&#xD;
          -  History of left or right carotid surgery&#xD;
&#xD;
          -  History of unilateral or bilateral vagotomy, partial or complete splenectomy&#xD;
&#xD;
          -  Recurrent vasovagal syncope episodes&#xD;
&#xD;
          -  Current, regular use of tobacco products&#xD;
&#xD;
          -  Hypersensitivity/allergy to MRI contrast agents and/or unable to perform MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey R Curtis, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama, Birmingham, AL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Richardson, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manager of Clinical Operations at SetPoint Medical</last_name>
    <phone>855-737-3872 (855RESETRA)</phone>
    <email>vhaines@setpointmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Call Center for RESET-RA</last_name>
    <phone>855-737-3872 (855RESETRA)</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laticia Woodruff</last_name>
      <email>lplove@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Curtis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristen Riley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis Rheumatology &amp; Research, PLLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Salazar</last_name>
      <email>brenda.salazar@azarthritis.com</email>
    </contact>
    <investigator>
      <last_name>John Tesser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Adelson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91722</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Rodriguez</last_name>
      <email>m.rodriguez@medvinresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Lupe Perez</last_name>
      <email>lupe@medvinresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Samy Metyas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Warren Boling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology Clinical Trials</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amalia Ellis</last_name>
      <email>aellis@irclinicaltrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Katheryn Castillo</last_name>
      <email>kcastillo@irclinicaltrials.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Warren Boling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nereyda Negrete</last_name>
      <email>nereyda@medvinresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Vipul Vineet</last_name>
      <email>vipul@medvinresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tien-I Karleen Su, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Warren Boling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stamford Therapeutics Consortium</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Stein</last_name>
      <email>jstein@stctrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Judy Dalgin</last_name>
      <email>jdalgin@stctrials.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stuart Novack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashesh Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delaware Arthritis</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Townsend</last_name>
      <email>ptownsend@delawarearthritis.com</email>
    </contact>
    <investigator>
      <last_name>Jose Pando, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howard M Eisenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRIS Research and Development</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Perez, MD</last_name>
      <email>kperez@valenzuelarheumatology.com</email>
    </contact>
    <investigator>
      <last_name>Guillermo Valenzuela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Vrionis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Broward Rheumatology Associates</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Florida Medical Clinic, LLC</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Division of Rheumatology, Allergy, and Immunology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Cogan</last_name>
      <email>ascogan@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Minna Kohler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>June DO, PC</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tresa Nelson</last_name>
      <email>tresa.nelson@glcor.com</email>
    </contact>
    <investigator>
      <last_name>Joshua June, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Schwalb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albuquerque Center for Rheumatology</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Ramirez</last_name>
      <email>valarr@qwestoffice.net</email>
    </contact>
    <contact_backup>
      <last_name>Valarie Jackson</last_name>
      <email>vjackson@abqrheum.net</email>
    </contact_backup>
    <investigator>
      <last_name>Leroy Pacheco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Botros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Droppelman</last_name>
      <email>Audrey.Droppelman@djlresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jane Box, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Van Poppel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Health Research of Oklahoma, PLLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlene Prescott</last_name>
      <email>cprescott@healthresearchok.com</email>
    </contact>
    <investigator>
      <last_name>Christine Codding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Perry Santos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Rosen</last_name>
      <email>ellenrosen@altoonaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Alan J Kivitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael D Sather, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Austin Regional Clinic</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78717</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian L Mills</last_name>
      <email>vlmills@austinregionalclinic.com</email>
    </contact>
    <investigator>
      <last_name>Anurekha B Chadha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Peterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tekton Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Holleran</last_name>
      <email>jholleran@tektonresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Rita Yankyera</last_name>
      <email>ryankyera@tektonresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Pickrell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Peterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwest Rheumatology Research LLC</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Delacruz</last_name>
      <email>ndelacruz@swrr.net</email>
    </contact>
    <investigator>
      <last_name>Atul Singhal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bradley Lega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Korte</last_name>
      <email>mkorte@cttexas.com</email>
    </contact>
    <contact_backup>
      <last_name>Alison Mortensen</last_name>
      <email>amortensen@cttexas.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pendleton Wickersham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Peterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Washington Arthritis Clinic</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <zip>98021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Lockhart</last_name>
      <email>klockhart@wwmedgroup.com</email>
    </contact>
    <investigator>
      <last_name>Jeff Peterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Ko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest Rheumatology, PLLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seinna Gray</last_name>
      <email>sgray@arthritisnw.com</email>
    </contact>
    <contact_backup>
      <last_name>Terri Cone</last_name>
      <email>tcone@arthritisnw.com</email>
    </contact_backup>
    <investigator>
      <last_name>Howard Kenney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Ko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Physicians and Surgeons, INC dba Marshall Health</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniell Gallgaher</last_name>
      <email>gallagherd@marshall.edu</email>
    </contact>
    <investigator>
      <last_name>Ralph Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tami Deal</last_name>
      <email>tldeal@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Jamie Latos, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Konrad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Vagus nerve</keyword>
  <keyword>vagus nerve stimulating device</keyword>
  <keyword>drug refractory</keyword>
  <keyword>permanent implantable</keyword>
  <keyword>implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No sharing data is planned.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

